Step by Step


2016-09-13 - Medical Grand Rounds: Immune Mechanisms in the Tumor Microenvironment & The 4th modality has arrived - Immunotherapy for Cancer





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Evaluate immune system cells and targets that mediate tumor escape and tumor progression.
  • Recognize therapeutic strategies targeting suppressive cells and receptor pathways to reverse immune escape.
  • Assess initial efficacy data from recent clinical trials of cancer immunotherapy.

Presentation Topics
Title:  Immune Mechanisms in the Tumor Microenvironment
Presenter:  Dario Vignali, PhD

Title:  The 4th modality has arrived - Immunotherapy for Cancer
Presenter:  Robert L. Ferris, MD, PhD

Suggested Additional Reading:

  1. JI-CE (2002)169:5392
  2. JI (2005) 174:688
  3. EMBOJ (2007) 26:494.
  4. Nature (2007) 450:566
  5. JI (2009) 182:6121
  6. Nature Immunology (2010) 11:1093
  7. Nature Immunology (2012) 13:290.
  8. Nature (2013) 501:252.
  9. Vignali et al (2008) Nature Reviews Immunology 8, 523.
  10. Galon et al. Science,2006;313:1960-1964
  11. Mellman I et al. Nature,2011;480:480-489.

Dario Vignali, PhD — Professor & Vice Chair of Immunology Co-Leader of the Cancer Immunology Program Co-Director of the Tumor Microenvironment Center University of Pittsburgh Department of Immunology
Dr. Vignali receives grant/research support, Potenza Therapeutics, Tizona Therapeutics. A Consultant with Potenza Therapeutics, Tizona Therapeutics, Oncorus, Pieris, Moderna, Opexa and stockholder with Potenza Therapeutics, Tizona Therapeutics and Oncorus.
Robert L. Ferris, MD, PhD — UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology Professor of Immunology and Radiation Oncology Co-leader, Cancer Immunology Program
Dr. Ferris receives grant/research support from Astra-Zeneca; BMS; Merck; VentiRx Pharmaceuticals. He also a member of the Advisory Board for Astra-Zeneca/MedImmune; BMS; Lilly; Merck; Pfizer.
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.